EP0721328A4 - Compositions de camptothecine - Google Patents

Compositions de camptothecine

Info

Publication number
EP0721328A4
EP0721328A4 EP94929892A EP94929892A EP0721328A4 EP 0721328 A4 EP0721328 A4 EP 0721328A4 EP 94929892 A EP94929892 A EP 94929892A EP 94929892 A EP94929892 A EP 94929892A EP 0721328 A4 EP0721328 A4 EP 0721328A4
Authority
EP
European Patent Office
Prior art keywords
camptothecin formulations
camptothecin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94929892A
Other languages
German (de)
English (en)
Other versions
EP0721328A1 (fr
Inventor
Panayiotis Peri Constantinides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0721328A1 publication Critical patent/EP0721328A1/fr
Publication of EP0721328A4 publication Critical patent/EP0721328A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94929892A 1993-09-27 1994-09-27 Compositions de camptothecine Withdrawn EP0721328A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12720893A 1993-09-27 1993-09-27
PCT/US1994/010898 WO1995008986A1 (fr) 1993-09-27 1994-09-27 Compositions de camptothecine
US127208 1998-07-31

Publications (2)

Publication Number Publication Date
EP0721328A1 EP0721328A1 (fr) 1996-07-17
EP0721328A4 true EP0721328A4 (fr) 1997-09-17

Family

ID=22428860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94929892A Withdrawn EP0721328A4 (fr) 1993-09-27 1994-09-27 Compositions de camptothecine

Country Status (3)

Country Link
EP (1) EP0721328A4 (fr)
JP (1) JPH09504517A (fr)
WO (1) WO1995008986A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115099A (en) * 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
CA2303366A1 (fr) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Compositions a base de liposomes renfermant de la camptothecine
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
NZ511112A (en) 1998-09-16 2003-11-28 Alza Corp Lipsome-entrapped topoisomerase inhibitors
DE60017359T2 (de) * 1999-01-27 2005-12-01 TELIK, INC., Palo Alto Glutathioneanaloge enthaltende therapeutische zusammensetzungen
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
ATE309787T1 (de) * 2000-06-30 2005-12-15 Inex Pharmaceuticals Corp Verbesserte liposomale camptothecine und deren verwendungen
AU2001278336B2 (en) 2000-07-31 2007-01-18 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
ATE413164T1 (de) * 2000-11-09 2008-11-15 Neopharm Inc Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
WO2002074246A2 (fr) * 2001-03-20 2002-09-26 New Century Pharmaceuticals, Inc. Procede et compositions permettant d'optimiser la stabilite du sang et des tissus conferee par la camptothecine et par d'autres composes therapeutiques liant l'albumine
DE10157994A1 (de) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomal verkapselte hydrophobe Wirkstoffe mit hohem Wirkstoffgehalt >50% sowie Verfahren zur Herstellung pharmazeutischer Zubereitungen, die liposomal verkapselte hydrophobe Wirkstoffe umfassen
WO2003030864A1 (fr) * 2001-05-29 2003-04-17 Neopharm, Inc. Formulation liposomale d'irinotecan
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
CA2492080A1 (fr) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Procede pour stabiliser des composes destines au diagnostic ou a la therapie dans un systeme support cationique
EP1393719A1 (fr) * 2002-08-23 2004-03-03 Munich Biotech AG Compositions à base de carboxylate de camptothécine
EP1629111B1 (fr) 2003-05-30 2008-05-28 University Of Chicago Methodes et compositions de prediction de toxicite de l'irinotecan
WO2005002546A1 (fr) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Compositions liposomales stabilisee de topotecane et procedes
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US7811602B2 (en) 2004-05-17 2010-10-12 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
CN100356919C (zh) * 2004-05-31 2007-12-26 上海医药工业研究院 羟基喜树碱脂质体及其制备方法
KR100889139B1 (ko) 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
CN1980671B (zh) * 2004-06-18 2011-10-19 泰尔茂株式会社 含有水难溶性喜树碱的脂质体制剂
EP1807051A2 (fr) * 2004-11-05 2007-07-18 Inex Pharmaceuticals Corporation Compositions et methodes destinees a stabiliser des preparations medicamenteuses liposomales
EP1676568A1 (fr) * 2004-12-30 2006-07-05 Merckle Gmbh Particules comprenant des phospholipides, procédé de préparation et utilisation comme médicament
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
SG10201407996PA (en) 2009-12-23 2015-01-29 Novartis Ag Lipids, lipid compositions, and methods of using them
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
US20150209281A1 (en) * 2012-07-18 2015-07-30 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
TR201908531T4 (tr) 2012-11-20 2019-08-21 Arbutus Biopharma Corp Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem
AU2014224205C1 (en) 2013-03-08 2019-04-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3872066A1 (fr) 2013-12-19 2021-09-01 Novartis AG Lipides et compositions lipidiques pour l'administration d'agents actifs
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
PL439632A1 (pl) * 2021-11-23 2023-05-29 Uniwersytet Warszawski Nośnik lipidowy leku, formulacja farmaceutyczna, ich zastosowania oraz sposób wytwarzania nośnika lipidowego leku, nośnik otrzymany takim sposobem oraz jego zastosowania

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026253A1 (fr) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome ayant une couche a composants multiples qui contient un agent bioactif en tant que composants integres dans la bicouche

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026253A1 (fr) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome ayant une couche a composants multiples qui contient un agent bioactif en tant que composants integres dans la bicouche

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9508986A1 *

Also Published As

Publication number Publication date
EP0721328A1 (fr) 1996-07-17
WO1995008986A1 (fr) 1995-04-06
JPH09504517A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
EP0721328A4 (fr) Compositions de camptothecine
HK1011278A1 (en) Macrolide formulations
IL111004A0 (en) Oral rapamycin formulations
ZA945653B (en) Therapeutic compositions
GB9207832D0 (en) Formulations
AP9400704A0 (en) Novel formulation
ZA946195B (en) Anthelmintic formulations
GB9410252D0 (en) Galenic formulations
GB9214390D0 (en) Formulations
GB9311030D0 (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9308622D0 (en) Formulations
GB9306144D0 (en) Formulations
GB9224539D0 (en) Formulations
GB9213271D0 (en) Formulations
GB9205739D0 (en) Formulations
GB9205738D0 (en) Formulations
GB9202474D0 (en) Formulations
GB9304797D0 (en) Pharmaceutical formulations
GB9304800D0 (en) Pharmaceutical formulations
GB9321676D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9315119D0 (en) Pharmaceutical formulations
GB9302908D0 (en) Pharmaceutical formulations
GB9314443D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19970731

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000401